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MaBACKGROUND Both pathological excess and deﬁciency of growth hormone (GH) are associated with cardiovascular
mortality.
OBJECTIVES The goal of this study was to test whether fasting levels of growth hormone measured with a
high-sensitivity assay (hs-GH) predict cardiovascular morbidity and mortality at the population level.
METHODS We studied 4,323 participants (age 46 to 68 years; mean age 58 years; 59% women) of the Swedish,
population-based Malmö Diet and Cancer study examined in 1991 to 1994. Using multivariate-adjusted Cox proportional
hazards models, we related baseline levels of fasting hs-GH to incidence of coronary artery disease, stroke, congestive
heart failure, all-cause mortality, and cardiovascular mortality.
RESULTS During a median follow-up of 16.2 years, hs-GH (hazard ratio [HR]/SD increment of natural logarithm of
fasting hs-GH) was independently associated with increased risk of coronary artery disease (397 events; HR: 1.11; 95%
conﬁdence interval [CI]: 1.01 to 1.23; p ¼ 0.04), stroke (251 events; HR: 1.18; 95% CI: 1.04 to 1.34; p ¼ 0.01), congestive
heart failure (107 events; HR: 1.25; 95% CI: 1.03 to 1.52; p ¼ 0.02), all-cause mortality (645 events; HR: 1.17; 95% CI:
1.08 to 1.26; p < 0.001) and cardiovascular mortality (186 events; HR: 1.43; 95% CI: 1.24 to 1.66; p < 0.001). The
addition of hs-GH to a model with conventional cardiovascular risk factors signiﬁcantly reclassiﬁed risk, with a category-
free net reclassiﬁcation improvement (>0) of 0.542 (95% CI: 0.205 to 0.840) in cardiovascular mortality.
CONCLUSIONS Higher values of hs-GH were associated with an increased risk of cardiovascular morbidity and
mortality. (J Am Coll Cardiol 2014;64:1452–60) © 2014 by the American College of Cardiology Foundation.Open access under CC BY-NC-ND license.G rowth hormone (GH) is secreted from theanterior pituitary gland and exerts meta-bolic effects throughout the entire life,
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AB BR EV I A T I O N S
AND ACRONYM S
CAD = coronary artery disease
CHF = congestive heart failure
GH = growth hormone
GHD = growth
hormone deﬁciency
HDL-C = high-density
lipoprotein cholesterol
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1453(6), and waist-hip ratio (6,7), and decreased high-
density lipoprotein cholesterol (HDL-C) (7). In these
patients, GH substitution therapy has favorably
affected some aspects of the cardiovascular risk proﬁle
(6,8–10). Although the effects on glucose homeostasis
may be negative (1,8,10), it can be tentatively assumed
that GH substitution is beneﬁcial. However, to date,
there have been no large, randomized, placebo-
controlled trials evaluating the effect of GH substitu-
tion on cardiovascular morbidity or mortality.SEE PAGE 1461
HR = hazard ratio
hs-GH = high-sensitivity
growth hormone
LDL-C = low-density
lipoprotein cholesterol
NRI = net reclassiﬁcation
improvement
NT-proBNP = N-terminal
pro-brain natriuretic peptideAt the opposite end of the spectrum, patients with
acromegaly, who suffer from excess secretion of
growth hormone, also exhibit elevated mortality rates
in cardiovascular and cerebrovascular diseases (11).
Contributing factors to this mortality are higher
prevalence of hypertension, diabetes, arrhythmias,
and cardiomyopathy with hypertrophy of the heart
(12,13). The 1999 study by Takala et al. (14) further
demonstrated the detrimental effects of GH excess
(14). In this study, administration of high-dose GH to
critically ill patients in an intensive care unit doubled
mortality rates compared with placebo.
Most published reports concern patients with
either GH excess or deﬁciency. However, the pro-
spective study of French policemen, which began in
the late 1960s and early 1970s with an 18-year follow-
up, showed that higher fasting GH levels are associ-
ated with elevated risks for premature all-cause
mortality and for cardiovascular mortality (15).
Accurate interpretation of plasma GH concentra-
tion has long been hampered by the release of GH in
pulses over the majority of the day. However, in the
morning hours, plasma GH concentration is relatively
stable (16–18) but is low and sometimes undetectable
with conventional GH assays. We used a new high-
sensitivity assay for plasma growth hormone mea-
surements (hs-GH), which is able to quantify with
high precision even the normally low range of GH
levels (19). Given the limited knowledge on the rela-
tionship between fasting plasma GH concentration
and development of cardiovascular morbidity and
mortality, we measured hs-GH in fasted plasma in a
large, healthy population and related hs-GH to risk of
coronary artery disease (CAD), stroke, congestive
heart failure (CHF), all-cause mortality, and cardio-
vascular mortality during long-term follow-up.
METHODS
The MDC (Malmö Diet and Cancer) study is a
population-based, prospective cohort of 28,449 in-
dividuals examined between 1991 and 1996 (20). Fromthis cohort, a random sample, examined be-
tween November 1991 and February 1994 (n ¼
6,103), was included in the MDC cardiovas-
cular cohort, with the primary aim of study-
ing the epidemiology of carotid artery disease
(21). After exclusion of individuals lacking
values from fasting plasma samples and thus
missing data on prevalence of diabetes mel-
litus or fasting values of HDL-C, LDL-C, or
GH, the cohort consisted of 4,452 persons. Of
these, 129 individuals had a history of CAD,
stroke, or CHF and were excluded from
further analysis. Thus, 4,323 persons, age 46
to 68 years, remained to comprise the pri-
mary study cohort.
All participants provided written consent,
and the Ethical Committee at Lund Univer-
sity, Lund, Sweden approved the study.At baseline (1991 to 1996), participants underwent
a medical history, physical examination, and labora-
tory assessment. Diabetes mellitus was deﬁned as
either self-report of a physician diagnosis, use of
diabetes medication, or fasting venous whole blood
glucose >6.0 mmol/l (109 mg/dl). Levels of HDL-C,
total cholesterol, creatinine, glycated hemoglobin
(HbA1c), and insulin were measured according to
standard procedures at the Department of Clinical
Chemistry, University Hospital of Malmö. LDL-C
levels were calculated according to the Friedewald
formula. Levels of N-terminal pro-brain natriuretic
peptide (NT-proBNP) were determined using the
Dimension RxL automated NT-proBNP method
(Siemens Diagnostics, Nürnberg, Germany) (22).
All samples of plasma and whole blood were
obtained after overnight fasting, and samples were
drawn between 7:30 AM and 9:00 AM. Further details
about the clinical examination can be found in the
Online Appendix.
GH levels were measured in stored fasting plasma
samples, which were frozen immediately to 80C at
the Malmö Diet and Cancer Study–Cardiovascular
Cohort baseline examination. The measurement was
made with a high-sensitivity chemiluminescence
sandwich immunoassay similar to 1 previously
described (SphingoTec GmbH, Borgsdorf, Germany)
(19). The analytical assay sensitivity (mean relative
light units of 20 determinations of GH free sample þ
2 SD) was 2 pg/ml GH. The functional assay sensitivity
(<20% interassay coefﬁcient of variation) was
10 pg/ml. The assay is further described in the Online
Appendix. Individuals with a GH value equal to
0 (n ¼ 13) were censored in all analyses and are not
included in the count of 4,323 persons discussed
earlier.
TABLE 1
n (% of w
Age, yrs
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Body mas
Antihyper
Diabetes m
LDL-C, mm
HDL-C, m
Current sm
Growth ho
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1454We examined 5 primary outcomes: CAD, stroke,
CHF, cardiovascular mortality, and total mortality.
The endpoints were retrieved through record linkage
of the personal identiﬁcation number of each Swedish
individual and the Swedish Hospital Discharge Reg-
ister, the Swedish Cause of Death Register, the Stroke
in Malmö Register, and the Swedish Coronary Angi-
ography and Angioplasty Registry. These registries
were previously described and validated for classiﬁ-
cation of outcomes (23–26). CAD was deﬁned as fatal
or nonfatal myocardial infarction, death due to
ischemic heart disease, percutaneous coronary inter-
vention, or coronary artery bypass grafting, which-
ever came ﬁrst. Stroke was deﬁned as fatal or nonfatal
stroke. Congestive heart failure was deﬁned as a fatal
or nonfatal episode of CHF. Cardiovascular mortality
was deﬁned as a cardiovascular disease as the cause
of death. Codes, which are the basis for the events,
are speciﬁed in the Online Appendix. Follow-up for
outcomes was extended to June 30, 2009.
Fasting values of hs-GH, insulin, and NT-proBNP
exhibited a right-skewed distribution and were
transformed into natural logarithms before analysis.
To determine if GH displayed any correlation with
traditional cardiovascular risk factors (27), cross-
sectional analyses were performed at baseline using
linear regression models with standardized logarith-
mic hs-GH as the dependent variable and age, sex,
current smoking, antihypertensive medication, dia-
betes mellitus, and the standardized values for: sys-
tolic blood pressure, BMI, HDL-C, and LDL-C as
independent variables entered either separately
(crude) or simultaneously (multivariate adjusted).
Multivariable Cox proportional hazard models were
performed to examine the association between GH
and incidence of cardiovascular events and mortality.
All models were adjusted for age, sex, systolic bloodClinical Characteristics of the Study Population
Male Female
hole cohort) 1,778 (41.1) 2,545 (58.9)
57.8  6.0 57.5  5.9
lood pressure, mm Hg 144  19 140  19
s index, kg/m2 26.1  3.4 25.5  4.2
tensive therapy 279 (15.7) 384 (15.1)
ellitus 197 (11.1) 162 (6.4)
ol/l 4.11  0.89 4.20  1.05
mol/l 1.22  0.30 1.51  0.37
okers 491 (27.6) 650 (25.5)
rmone, mg/l 0.11 (0.06–0.33) 1.22 (0.40–3.15)*
(%), mean  SD, or median (interquartile range). *Signiﬁcant difference vs. males
). The p value for differences in other variables not calculated.
high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol.pressure, use of antihypertensive medication, current
smoking, diabetes mellitus, BMI, and levels of LDL-C
and HDL-C. We conﬁrmed that the proportionality of
hazards assumption was met using Schoenfeld re-
siduals. Hazard ratios (HRs) for GH were expressed per
1-SD increment of the natural logarithm of hs-GH.
Values of hs-GH were standardized separately in
each sex before being used in sex-combined models,
due to the large difference of hs-GH between the
sexes. To establish if there were any signiﬁcant sex
differences, a sex interaction test was performed. A
limited number of other cardiovascular risk factors or
factors assumed to be associated with GH (NT-
proBNP, creatinine, waist circumference, body fat
percentage, insulin, and HbA1c) were then added to
the models to evaluate the stability of the results.
To evaluate if GH had any predictive potential we
calculated the category-free net reclassiﬁcation
improvement (NRI) (>0) according to previously
described methods (28). We used multivariable risk
scores with the parameters mentioned in the pre-
ceding text to estimate the risk of developing a
cardiovascular event and then examined whether the
addition of hs-GH improved the model and re-
classiﬁed subjects, thus obtaining the NRI (>0).
Up-classiﬁcation in the risk of individuals who
developed an event or down-classiﬁcation of in-
dividuals who did not develop an event improves the
risk model, whereas the opposite deteriorates the
model. Calculation of C statistics (Harrell’s) (29) was
used to assess model discrimination.
A post-hoc analysis was made examining the case
fatality of myocardial infarctions versus hs-GH. Case
fatality was deﬁned as death within 24 h of the event.
Odds ratios were calculated by means of logistic
regression analyses and adjusted for the risk factors
included in our original model, with the addition of
year of event and age at event replacing age at base-
line. Odds ratios for GH were expressed per 1-SD
increment of the natural logarithm of hs-GH.
All analyses were made with Stata software version
11 (StataCorp, College Station, Texas). A 2-sided
p value <0.05 was considered statistically signiﬁcant.
RESULTS
Women had signiﬁcantly higher fasting values of
hs-GH than men (Table 1). Individuals excluded from
the study due to missing plasma samples or prevalent
cardiovascular disease differed slightly in their base-
line characteristics (Online Table 1).
With the exception of age in women and systolic
blood pressure and antihypertensive medication in
men (Online Table 2), most variables were signiﬁcant
TABLE 2 Results From Multiple Linear Regression Models Examining Correlations
Between Fasting Values of Growth Hormone and Traditional Cardiovascular Risk Factors
Risk factor
Male Female
b
Coefﬁcient* 95% CI p Value
b
Coefﬁcient* 95% CI p Value
Age 0.02 0.01 to 0.03 <0.001 0.02 0.01 to 0.02 <0.001
Systolic blood
pressure
0.02 0.03 to 0.07 0.38 0.04 0.08 to 0.00 0.04
Antihypertensive
medication
0.13 0.00 to 0.26 0.05 0.07 0.03 to 0.18 0.18
BMI 0.07 0.12 to 0.03 0.003 0.25 0.29 to 0.21 <0.001
Current smoking 0.29 0.19 to 0.39 <0.001 0.19 0.10 to 0.27 <0.001
LDL-C 0.09 0.13 to 0.04 <0.001 0.10 0.14 to 0.06 <0.001
HDL-C 0.20 0.15 to 0.25 <0.001 0.08 0.04 to 0.12 <0.001
Diabetes mellitus 0.21 0.07 to 0.36 0.004 0.16 0.31 to 0.00 0.05
*The b coefﬁcients are expressed as the increment of standardized values of the natural logarithm of high-
sensitivity growth hormone per 1 increment of standardized values (or presence of dichotomized risk factor)
of the risk factor in question. NB age is not standardized. BMI (weight [kg] divided by height [m2]), systolic blood
pressure, and fasting values of HDL-C and LDL-C are standardized. Prevalence of diabetes mellitus, current
smoking, and use of antihypertensive medication are dichotomous variables.
BMI ¼ body mass index; other abbreviations as in Table 1.
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1455determinants of hs-GH in the crude regression
models. In the adjusted models, age, current smok-
ing, and HDL-C had a signiﬁcant positive correlation
with hs-GH, whereas LDL-C and BMI exhibited sig-
niﬁcant negative correlation in both sexes (Table 2,
Online Tables 3 and 4). Prevalence of diabetes melli-
tus had a positive correlation with hs-GH in males and
a negative correlation in females. The multiple
regression models had an R2 value of 9.5% for males
and 11.8% for females.
Median follow-up time ranged from 16.1 years
(interquartile range: 15.4 to 16.7 years) in CAD to 16.2
years (interquartile range: 15.6 to 16.7 years) in the
mortality analyses. Total follow-up time was more
than 66,000 person-years. All of the Cox proportional
hazards models were signiﬁcant when analyzing the
whole cohort, with increasing hs-GH levels associated
with elevated cardiovascular morbidity and mortal-
ity, independent of other cardiovascular risk factors
(Table 3). HRs for each SD increase of baseline hs-GH
ranged from 1.11 in CAD to 1.43 in cardiovascular
mortality. A total of 4 of 5 male analyses were sig-
niﬁcant, with HRs ranging from 1.17 in CAD to 1.44 in
cardiovascular mortality, and the 5th analysis, which
was CHF, was nonsigniﬁcant. In females, HRs were
signiﬁcant for cardiovascular mortality (1.45) and
CHF (1.48). A signiﬁcant sex interaction was found in
the analysis of total mortality (p ¼ 0.02).
When comparing the quartile with the highest
values of hs-GH with the bottom quartile, HRs ranged
from 1.33 (95% conﬁdence interval [CI]: 0.99 to 1.79;
p¼ 0.05) in CAD to 2.83 (95% CI: 1.74 to 4.61; p< 0.001)
in cardiovascular mortality (Table 3). Male HRs were
signiﬁcant in CAD (HR: 1.45; 95% CI: 1.01 to 2.08;
p ¼ 0.05), total mortality (HR: 2.05; 95% CI: 1.44 to
2.92; p < 0.001), and cardiovascular mortality (HR:
3.32; 95% CI: 1.65 to 6.70; p < 0.001). Female quartile
analyses were signiﬁcant in cardiovascular mortality
(HR: 2.36; 95% CI: 1.16 to 4.80; p ¼ 0.02) when
comparing the highest quartile of hs-GH to the lowest.
We investigated whether our ﬁndings were inde-
pendent of known GH-associated variables and other
cardiovascular risk factors by adding insulin,
HbA1c, creatinine, NT-proBNP, waist circumference,
and body fat percentage to the different Cox models
mentioned previously. Generally, these variables had
only minor effects on HRs or CIs, with NT-proBNP and
HbA1c having the largest effects, resulting in a slight
attenuation of some results (Online Tables 5 and 6). If
the analyses were performed crude, the results were
similar, but not identical (Online Table 7, Online
Figures 1 to 9).
In the reclassiﬁcation analyses, the NRI (>0) was
signiﬁcant for the whole cohort in stroke (0.179;95% CI: 0.003 to 0.293), total mortality (0.207; 95%
CI: 0.020 to 0.383), and cardiovascular mortality
(0.542; 95% CI: 0.205 to 0.840) (Table 4, Online
Table 8). The 2 mortality analyses were signiﬁcant
for males, whereas the female analyses were signiﬁ-
cant in cardiovascular mortality. Improvement mostly
stemmed from down-classiﬁcation of nonevents in
the total mortality analysis and up-classiﬁcation of
events in cardiovascular mortality. To evaluate the
reclassiﬁcation model, we tried adding creatinine
and NT-proBNP to the basic model before calculating
the NRI (>0) for hs-GH. This attenuated the NRI
(>0) in stroke and total mortality, whereas the associ-
ation in cardiovascular mortality remained the same
(Table 4).
Overall, the effects on the C-statistics when adding
GH to the basic model were modest. In analysis of
cardiovascular mortality the C-statistics increased
from 0.783 (95% CI: 0.752 to 0.814) to 0.794 (95% CI:
0.763 to 0.825) in the whole cohort, 0.751 (95% CI:
0.705 to 0.797) to 0.764 (95% CI: 0.719 to 0.809) in
males, and 0.797 (95% CI: 0.751 to 0.844) to 0.807
(95% CI: 0.760 to 0.854) in females (Table 5).
A post-hoc analysis of the 24-h case fatality of
myocardial infarctions versus hs-GH was performed
to investigate the strong relationship between hs-GH
and cardiovascular mortality. In a multivariate-
adjusted logistic regression, the odds ratio per 1-SD
increment of fasting hs-GH at baseline was 1.54
(310 events, 69 fatal; 95% CI: 1.13 to 2.09; p ¼ 0.006)
in the total cohort, 1.50 (187 events, 37 fatal;
95% CI: 1.00 to 2.23; p ¼ 0.05) among males, and 1.67
(123 events, 32 fatal; 95% CI: 0.98 to 2.85; p ¼ 0.06)
among females.
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We examined whether fasting values of hs-GH predict
cardiovascular morbidity and mortality in a large
population-based cohort free from CAD, CHF, and
stroke at baseline with a longitudinal follow-up time
exceeding 66,000 person-years. Increasing fasting hs-
GH levels were associated with higher incidence of
CAD, stroke, CHF, all-cause mortality, and cardio-
vascular mortality, independent of traditional car-
diovascular risk factors.
Adult GHD patients have an adverse cardiovascular
risk factor proﬁle (6,7) and were reported to have an
increased risk of all-cause and cardiovascular mortal-
ity (2–4). Although GH substitution ameliorates some
aspects of the cardiovascular risk factor proﬁle
(6,8–10), there are no randomized placebo-controlled
trials evaluating this therapy in relation to hard end-
points such as cardiovascular morbidity andmortality.
Interestingly, at the population level, we found that
patients with low hs-GH levels resembled GHD pa-
tients in having an unfavorable body composition and
lipoprotein proﬁle (Online Table 9). However, the
relationship between hs-GH and cardiovascular
morbidity and mortality was the opposite of that ex-
pected from the observations in GHD patients: sub-
jects with low hs-GH had low risk, whereas subjects
with high hs-GH had high risk. Although our study was
performed in healthy subjects and does not prove a
causal relationship between increasing GH and car-
diovascular morbidity and mortality, it does cast
doubts on whether GH replacement therapy in adult
GHD patients is beneﬁcial for cardiovascular health.
Most commonly, GHD patients are deﬁcient for a
reason, and previous cranial irradiation, surgery, and
other causes may affect mortality rates independently
from GHD. Rather, our results, together with the only
previous study of fasting GH in relation to all-cause
and cardiovascular mortality in healthy subjects (15),
suggest that elevated fasting GH is an independent
risk factor for cardiovascular morbidity and mortality,
and thus call for randomized placebo-controlled trials
of GH replacement therapy to determine its effect on
cardiovascular morbidity and mortality.
Today, GH use is not limited to individuals with
GHD. For example, GH has been used as an antiaging
therapy, and athletes also use it. A systematic review
concluded that GH could not be recommended as
antiaging therapy, and our results further highlight
the impropriety and possible dangers of this practice
(30). The use of GH in sports is classed as doping, and
its performance-enhancing capabilities are, in many
areas, doubtful (31). Physical exercise results in
secretion of GH; however, regular exercise has not
TABLE 4 Reclassiﬁcation of Risk Estimates (Category-Free NRI [>0]) for Addition of Growth Hormone to 1 Model With
Conventional Cardiovascular Risk Factors (Basic) and 1 Model With 2 Additional Risk Factors*
Basic Basic þ NT-proBNP þ Creatinine
Overall NRI (95% CI) Events (95% CI)* Nonevents (95% CI)* Overall NRI (95% CI)*
CAD All 0.081 (0.035 to 0.185) — — —
Male 0.143 (0.011 to 0.314) — — —
Female 0.144 (0.145 to 0.313) — — —
Stroke All 0.179 (0.003 to 0.293) 0.082 (0.053 to 0.162) 0.097 (0.451 to 0.156) 0.155 (0.032 to 0.288)
Male 0.178 (0.015 to 0.354) — — —
Female 0.191 (0.047 to 0.383) — — —
CHF All 0.115 (0.122 to 0.376) — — —
Male 0.142 (0.148 to 0.407) — — —
Female 0.248 (0.125 to 0.530) — — —
Total mortality All 0.207 (0.020 to 0.383) 0.084 (0.060 to 0.239) 0.122 (0.058 to 0.178) 0.208 (0.008 to 0.449)
Male 0.539 (0.131 to 0.983) 0.116 (0.131 to 0.482) 0.422 (0.258 to 0.655) 0.538 (0.129 to 1.099)
Female 0.041 (0.057 to 0.179) — — —
Cardiovascular
mortality
All 0.542 (0.205 to 0.840) 0.394 (0.089 to 0.727) 0.147 (0.068 to 0.288) 0.564 (0.180 to 0.864)
Male 0.853 (0.166 to 1.633) 0.411 (0.083 to 1.064) 0.442 (0.203 to 0.711) 0.872 (0.177 to 1.571)
Female 0.332 (0.137 to 0.564) 0.277 (0.110 to 0.466) 0.055 (0.029 to 0.145) 0.370 (0.032 to 0.625)
Variables included in the original model: sex, age, systolic blood pressure, body mass index, antihypertensive medication, current smoking, diabetes mellitus, LDL-C, and
HDL-C. *Data in “events,” “nonevents,” and the extended model are only shown in the outcomes where the basic overall NRI is signiﬁcant.
NRI ¼ net reclassiﬁcation improvement; NT-proBNP ¼ N-terminal probrain natriuretic peptide; other abbreviations as in Tables 1 and 3.
TABLE 5 Improvement of Discrimination (C-Statistics) of 10-Year Risk Estimates for
Addition of Growth Hormone to a Model With Conventional Cardiovascular Risk Factors
Outcome Sex Basic (95% CI) þGH (95% CI)
CAD All 0.748 (0.726–0.771) 0.749 (0.726–0.772)
Male 0.696 (0.665–0.726) 0.698 (0.667–0.729)
Female 0.744 (0.707–0.782) 0.744 (0.707–0.782)
Stroke All 0.753 (0.726–0.780) 0.757 (0.730–0.784)
Male 0.745 (0.708–0.781) 0.749 (0.712–0.785)
Female 0.749 (0.709–0.789) 0.752 (0.713–0.791)
CHF All 0.782 (0.739–0.825) 0.786 (0.743–0.828)
Male 0.784 (0.725–0.845) 0.784 (0.724–0.844)
Female 0.789 (0.724–0.853) 0.801 (0.737–0.865)
Total mortality All 0.711 (0.691–0.730) 0.714 (0.695–0.734)
Male 0.700 (0.673–0.727) 0.709 (0.683–0.736)
Female 0.703 (0.674–0.732) 0.703 (0.674–0.733)
Cardiovascular mortality All 0.783 (0.752–0.814) 0.794 (0.763–0.825)
Male 0.751 (0.705–0.797) 0.764 (0.719–0.809)
Female 0.797 (0.751–0.844) 0.807 (0.760–0.854)
Harrell’s c-statistic. Area under the receiver-operating characteristics curve in basic model without hs-GH (basic)
and the basic model with addition of hs-GH (þGH). Variables included in the original model: sex, age, systolic
blood pressure, body mass index, antihypertensive medication, current smoking, diabetes mellitus, LDL-C, and
HDL-C.
Abbreviations as in Tables 1 and 3.
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1457been shown to alter the baseline resting levels (32),
which may indicate that regular physical activity does
not affect the fasting value of GH.
As would be expected, studies in rodents showed
that mice overexpressing GH genes have a drastically
shortened life span (33). What is more surprising is
that mice that are either missing the GH receptor
(growth hormone receptor knockout, GHRKO) or
Ames mice (deﬁcient in GH, prolactin, and thyroid-
stimulating hormone) live longer than normal mice
(34,35) while being obese compared with their sib-
lings (36,37). Although the relevance of these exper-
imental data for humans is unclear, they suggest a
link between reduced GH signaling and a phenotype
of obesity and longer life span. This somewhat re-
sembles the situation in humans with low hs-GH who
have higher BMIs, waist circumference, and body fat,
but live longer in comparison with subjects with high
hs-GH (Central Illustration).
The outcome with the strongest independent rela-
tionship to baseline fasting hs-GH was cardiovascular
mortality. In this outcome, adding hs-GH to traditional
cardiovascular risk factors resulted in increments of
the NRI (>0) of 0.542 in the total cohort, suggesting
that addition of hs-GH improved the basic predictive
model. Even with the addition of creatinine and NT-
proBNP, the association remained signiﬁcant. Inter-
estingly, the NRI (>0) in cardiovascular mortality was
driven to a larger extent by up-classiﬁcation of sub-
jects with a cardiovascular death than by down-
classiﬁcation of healthy subjects. Even though theclinical use of hs-GH for prediction would be associ-
ated with many drawbacks, these results still indicate
that the predictive possibility is not negligible.
In general, we found a stronger relationship
between hs-GH in men than in women. There are
several potential explanations for this. Our ﬁnding
that women have in the order of 10-fold higher
values of fasting GH than men has been previously
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CENTRAL ILLUSTRATION Brief Summary of the Relation Between GH, Risk Factors, and Cardiovascular Diseases
Schematic ﬁgure shows links between GH levels and cardiovascular diseases found in research on animals and humans. BMI ¼ body mass index;
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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1458described (38). The 24-h proﬁles of GH secretion in
women were shown to be more irregular and to have
shorter oscillatory periods and higher trough values
than in men (39–41). It should be kept in mind that
fasting GH values are not a standard clinical test, and
it is not known how these values relate to overall GH
production. When examining 24-h GH proﬁles from
previous publications, morning values in men appear
quite low and stable, whereas the variation in women
is larger (16–18). It can thus be speculated that the
more stable GH levels in the morning hours in men
than in women makes a single fasting hs-GH a more
accurate measure of GH secretion in men, which, in
turn, could explain why associations with various
outcomes are stronger in males. Part of the sex
discrepancy may also be attributable to power dif-
ferences, as all outcomes occurred at a higher inci-
dence rate in the male population.
STUDY LIMITATIONS. To date, it is unclear to what
extent a fasting value of hs-GH reﬂects overall GH
secretion. The pulsatile mode of secretion is a limi-
tation and makes GH difﬁcult to use in a clinical
setting. It is not clear whether our ﬁndings represent
a linear relationship between GH and the various
outcomes, although the quartile analyses were done
to evaluate this. Unfortunately, splitting the material
caused power difﬁculties and made a clear-cut
answer impossible. An effort to analyze the 10th and90th percentile versus the middle (data not shown)
was also hampered by power, but did not indicate a
different association. In addition, we did not measure
circulating or tissue insulin-like growth factor-1,
which mediates several effects of GH. Despite these
issues, we did observe relationships between hs-GH
and GH-related phenotypes at baseline as well as as-
sociations with long-term outcomes, especially the
risk of cardiovascular mortality, suggesting that
fasting hs-GH does reﬂect a medically relevant
measure. The association of higher hs-GH values with
increased likelihood of a myocardial infarction being
fatal may explain why our strongest ﬁndings were in
the cardiovascular mortality outcome.
Because this was an observational study, we do not
prove causation between hs-GH and our various
endpoints. Also, the number of nonaccepters to the
initial invitation was quite large, which could have
biased selection of a more healthy population.
Although GH secretion is known to have a strong
positive correlation with estradiol levels, we have not
excluded pre-menopausal or perimenopausal women
from the study (42); this may be a potential
confounder in the female analyses. However, the
consequence of this would be younger women
exhibiting higher GH values, which logically would
weaken a positive correlation between hs-GH and the
various outcomes. Differences in baseline character-
istics in people excluded due to missing plasma
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In healthy
middle-aged people, higher fasting levels of GH are associated
with greater cardiovascular morbidity and mortality independent
of traditional cardiovascular risk factors.
COMPETENCY IN PATIENT CARE: In healthy middle-aged
individuals, measurement of fasting GH in plasma may be
useful in risk stratiﬁcation for cardiovascular mortality and aid
clinical decision-making for primary prevention of ischemic
events.
TRANSLATIONAL OUTLOOK: Randomized trials are needed
to investigate the effect of GH replacement on cardiovascular
outcomes in patients with GHD.
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1459samples compared with the study cohort were minor
and did not raise any suspicions of selection bias.
CONCLUSIONS
We demonstrate that higher fasting values of hs-GH
are associated with cardiovascular morbidity, all-
cause mortality, and, in particular, cardiovascular
mortality. Further research is needed to elucidate the
mechanisms of this association in the general popu-
lation and its potential implications in the subgroups
of patients with a disturbance in GH secretion.
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